Benefits of Leveraging Real World Data (RWD) to Conduct Long-Term Follow Up

Conducting long-term follow up studies to ensure that life-saving therapies can be brought to patients safely is challenging. This places a burden on patients participating in the studies and operational challenges on life sciences study sponsors.

Connecting sources of real world data (RWD) to clinical trials data can create a more seamless process for conducting long-term follow up studies.

In this webinar, panelists will discuss how this approach enables many benefits, including the ability to: 

• Supplement data for patients lost to follow up
• Augment trial data to help explain non-responders and adverse events 

This approach can be particularly beneficial in specific therapeutic areas, including: 

• Cell and gene therapies: high regulatory burden (up to 15 years of data collection)
• Oncology: endpoints such as overall survival can be assessed for Accelerated Approval
• COVID-19: exploration of delayed adverse events